PMID- 31659107
OWN - NLM
STAT- MEDLINE
DCOM- 20200311
LR  - 20211124
IS  - 1790-6245 (Electronic)
IS  - 1109-6535 (Print)
IS  - 1109-6535 (Linking)
VI  - 16
IP  - 6
DP  - 2019 Nov-Dec
TI  - PRIMA-1(MET) Induces Cellular Senescence and Apoptotic Cell Death in 
      Cholangiocarcinoma Cells.
PG  - 543-552
LID - 10.21873/cgp.20156 [doi]
AB  - BACKGROUND/AIM: This study examined the in vitro effects of the bile duct cancer 
      drug PRIMA-1(MET) on cholangiocarcinoma (CCA) cell growth to determine its 
      potential usefulness in CCA therapy. MATERIALS AND METHODS: The effect of this 
      drug on the expression of senescent markers (p16(INK4A) and p21) and the 
      phosphorylation of p53 was investigated, as was the association between senescent 
      markers and the patients' clinicopathological data. RESULTS: PRIMA-1(MET) 
      inhibited CCA cell growth with the half maximal-inhibitory concentration (IC(50)) 
      values of 21.9-40.8 muM. PRIMA-1(MET) induced phospho-p53, p16(INK4A) and p21 
      triggering cellular senescence and apoptosis. High expressions of p16(INK4A) and 
      p21 were associated with a high survival rate of patients with CCA. CONCLUSION: 
      PRIMA-1(MET) may potentially be an alternative anticancer agent that might lead 
      to a better prognosis in patients with CCA.
CI  - Copyright(c) 2019, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Piyawajanusorn, Chayanit
AU  - Piyawajanusorn C
AD  - Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
AD  - Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen, Khon 
      Kaen, Thailand.
FAU - Kittirat, Yingpinyapat
AU  - Kittirat Y
AD  - Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
AD  - Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen, Khon 
      Kaen, Thailand.
FAU - Sa-Ngiamwibool, Prakasit
AU  - Sa-Ngiamwibool P
AD  - Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen, Khon 
      Kaen, Thailand.
AD  - Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
FAU - Titapun, Attapol
AU  - Titapun A
AD  - Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen, Khon 
      Kaen, Thailand.
AD  - Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
FAU - Loilome, Watcharin
AU  - Loilome W
AD  - Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
AD  - Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen, Khon 
      Kaen, Thailand.
FAU - Namwat, Nisana
AU  - Namwat N
AD  - Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand nisana@kku.ac.th.
AD  - Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen, Khon 
      Kaen, Thailand.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Cancer Genomics Proteomics
JT  - Cancer genomics & proteomics
JID - 101188791
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Quinuclidines)
RN  - Z41TGB4080 (eprenetapopt)
SB  - IM
MH  - Apoptosis/*drug effects
MH  - *Bile Duct Neoplasms/drug therapy/metabolism/pathology
MH  - Cell Line, Tumor
MH  - Cellular Senescence/*drug effects
MH  - *Cholangiocarcinoma/drug therapy/metabolism/pathology
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Neoplasm Proteins/biosynthesis
MH  - Quinuclidines/*pharmacology
PMC - PMC6885363
OTO - NOTNLM
OT  - Cellular senescence
OT  - PRIMA-1MET
OT  - apoptosis
OT  - cholangiocarcinoma
COIS- The Authors declare that no competing interest exists in regard to this study.
EDAT- 2019/10/30 06:00
MHDA- 2020/03/12 06:00
PMCR- 2019/11/03
CRDT- 2019/10/30 06:00
PHST- 2019/07/10 00:00 [received]
PHST- 2019/07/22 00:00 [revised]
PHST- 2019/07/24 00:00 [accepted]
PHST- 2019/10/30 06:00 [entrez]
PHST- 2019/10/30 06:00 [pubmed]
PHST- 2020/03/12 06:00 [medline]
PHST- 2019/11/03 00:00 [pmc-release]
AID - 16/6/543 [pii]
AID - 10.21873/cgp.20156 [doi]
PST - ppublish
SO  - Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):543-552. doi: 10.21873/cgp.20156.